Steven Cohen Catalyst Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 618,296 shares of CPRX stock, worth $12.3 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
618,296
Previous 618,296
-0.0%
Holding current value
$12.3 Million
Previous $9.58 Million
-0.0%
% of portfolio
0.03%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding CPRX
# of Institutions
286Shares Held
96.7MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$372 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$181 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$161 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$120 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$59.7 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.04B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...